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α-Synuclein is postulated to play a key role in the pathogenesis of Parkinson’s 
disease (PD). Aggregates of α-synuclein contribute to neurodegeneration and cell 
death in humans and in mouse models of PD. Here, we use virally mediated RNA 
interference to knockdown human α-synuclein in mice. We used an siRNA design 
algorithm to identify eight siRNA sequences with minimal off-targeting potential. One 
RNA-interference sequence (miSyn4) showed maximal protein knockdown potential 
in  vitro. We then designed AAV vectors expressing miSyn4 and injected them into 
the mouse substantia nigra. miSyn4 was robustly expressed and did not detectably 
change dopamine neurons, glial proliferation, or mouse behavior. We then injected 
AAV2-miSyn4 into Thy1-hSNCA mice over expressing α-synuclein and found 
decreased human α-synuclein (hSNCA) in both midbrain and cortex. In separate mice, 
co-injection of AAV2-hSNCA and AAV2-miSyn4 demonstrated decreased hSNCA 
expression and rescue of hSNCA-mediated behavioral deficits. These data suggest 
that virally mediated RNA interference can knockdown hSNCA in vivo, which could be 
helpful for future therapies targeting human α-synuclein.
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inTrODUcTiOn
α-Synuclein is an unstructured soluble protein involved in presynaptic processing of neurotrans-
mitters, mitochondrial function, and proteasome processing (1, 2). In Parkinson’s disease (PD), 
α-synuclein aggregates in Lewy bodies, which contributes to cellular dysfunction (3). Mutations 
and polymorphisms of the human synuclein (hSNCA) gene have been identified in the brain 
tissues of patients with PD (4). Humans with α-synuclein gene duplications have a dramatically 
increased risk of PD (5, 6). Mice engineered to overexpress mutant human α-synuclein (A53T) 
in CNS neurons have profound neurodegeneration with characteristic histopathologic features 
of PD, marked behavioral dysfunction, and motor impairments (7). Mouse models with virally 
overexpressed α-synuclein in the midbrain recapitulate behavioral dysfunction and motor impair-
ments (8, 9). These data implicate α-synuclein as a contributing protein in PD.
Although α-synuclein is involved in a variety of crucial physiological functions (10), 
α-synuclein knockout mice have relatively few neuroanatomical and motor deficits (11, 12) 
and are somewhat resistant to neurotoxins targeting dopamine neurons (13, 14). Thus reduction 
of α-synuclein has the potential to disrupt the chain of events causing protein aggregation and 
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cell death in PD. In addition, α-synuclein in the cerebral cortex 
may contribute to Lewy-body dementia (DLB) and dementia 
in PD (15).
These data suggest that decreasing α-synuclein expression 
might be a viable neuroprotective strategy. Various strategies 
have been used to knockdown α-synuclein (16–20). Early studies 
using virally mediated RNAi targeting rat α-synuclein resulted in 
dopaminergic neuron toxicity (17, 18). A subsequent study sub-
sequently used a microRNA-based strategy which yielded some 
neuroprotection but also inflammation and reduced expression 
of tyrosine hydroxylase, the rate-limiting enzyme for dopamine 
synthesis (21). Knocking down rodent α-synuclein can be protec-
tive in toxin-based animal models (20). In the present study, we 
harnessed bioinformatic algorithms to design small, interfering 
RNAs (siRNAs, 22–25). This technique has the potential to facili-
tate the safe and effective knockdown of toxic proteins in brain 
(26, 27). Here, we used this approach to design an RNAi targeting 
human α-synuclein and tested this approach in vitro and in vivo 
in mice.
resUlTs
In Vitro silencing of hsnca
The goal of the present study was to test if virally mediated RNAi 
decreased expression of human α-synuclein in mouse models. 
We used siRNA sequence probability-of-off-targeting reduction 
(siSPOTR) tools to identify siRNA sequences with minimal 
off-targeting potential and identified eight candidate sequences, 
labeled miSyn1–8 (Figure 1A; Table 1). We tested the efficacy of 
these eight sequences by cotransfecting hSNCA and miSyn1–8 
into HEK293 cells and assessed protein expression at 48  h by 
western blot. The cotransfection of miSyn3–5 showed reduced 
hSNCA protein expression relative to controls (miSyn3; 8 ± 4% 
of control, t = 24, p < 0.02; miSyn4 7 ± 3% of control, t = 29, 
p < 0.001; miSyn5 0 ± 0% of control, t = 745, p = 0; Figure 1B; 
n =  6 samples for miSyn1–8). Other clones were not effective. 
Based on this in  vitro data and the fact that miSyn4 showed 
limited silencing against rodent synuclein (Table 2), we selected 
miSyn4 for further characterization.
Next, we tested the efficacy of miSyn4 by qPCR. We cotrans-
fected hSNCA and miSyn4 as well as a scrambled control 
sequence in HEK 293 cells (positive control in Figures 1B–D) and 
measured hSNCA levels at 48 h via qPCR. We found that there 
was significantly less hSNCA in cells transfected with miSyn4 
compared to positive controls (t = 22, p < 0.03; n = 8; Figure 1C). 
We also transfected a separate group of HEK293 cells with mouse 
α-synuclein and measured levels of mouse α-synuclein at 48 h 
via qPCR. We found that miSyn4 did not influence the levels of 
mouse SNCA in vitro as measured by qPCR (n = 9; Figure 1D). 
These data demonstrate the miSyn4 can decrease expression of 
hSNCA in vitro.
aaV2-misyn4 expression In Vivo
Next, we wanted to test miSyn4 expression in  vivo. We cloned 
miSyn4 into a vector co-expressing eGFP to facilitate visualiza-
tion of viral transduction (22) (Figures 2A–C). AAVs have been 
used extensively to express RNAi molecules in  vivo (28). We 
tested the efficacy of the miSyn4 expression system by injecting 
AAV2-miSyn4 into the substantia nigra of wild-type mice and 
examining expression of miSyn4. Semiquantitative PCR found 
miSyn4 expression of mice only in the injected side (Figure 2C). 
miSyn4 was expressed in both TH+ and TH− cells (6 ± 2 TH+ 
eGFP+ cells/high power field vs 4 ± 1 DAPI+ eGFP+ cells/high 
power field; n = 5 mice; Figure 3).
Previous studies have reported decreased TH+ expression 
with α-synuclein RNAi (16). To examine if miSyn4 produced 
affected the number of TH+ cells, we counted the number to TH+ 
cells and GFAP+ cells in the midbrain of mice 90 days after mice 
were unilaterally injected with AAV2-eGFP or AAV2-miSyn4 
in the substantia nigra. We found that AAV2-miSyn4 did not 
change TH+ cell or GFAP+ cell counts by fluorescent immuno-
histochemistry (Figure 4A; n = 5 mice). Finally, AAV2-miSyn4 
expression for 90  days did not induce detectable behavioral 
changes as measured by open-field activity, number of rearings 
in the cylinder test, rotarod latency, the time to traverse a bal-
ance beam, beam slips, or contralateral circling (Figure 4B; n = 5 
mice). Mice with dysfunctional dopamine neurons are impaired 
in these tasks (29). These data indicate thatAAV2-miSyn4 can be 
tolerable in wild-type mice.
aaV2-misyn4 attenuates hsnca 
Overexpression In Vivo
Thus far, we have demonstrated the miSyn4 decreases α-synuclein 
in vitro and can be expressed in mice without overt neuroana-
tomical or behavioral changes. We turned to two animal models 
of α-synuclein overexpression to test if AAV2-miSyn4 can effec-
tively reduce hSNCA expression in  vivo. First, we investigated 
the Thy1-SNCA mouse (30, 31), which overexpresses wild-type 
hSNCA throughout the nervous system. This mouse was selected 
as a proof-of-principle model for high levels in in vivo expres-
sion; we selected 2-month-old mice because we wanted to study 
α-synuclein expression prior to the onset of marked neurodegen-
eration (32). We injected AAV2-miSyn4 or AAV2-eGFP into the 
substantia nigra of 2-month-old Thy1-SNCA mice and examined 
SNCA expression by qPCR (Figure  5A). AAV2-miSyn4 sig-
nificantly decreased hSNCA expression in the substantia nigra 
(47 ± 6 vs 98 ± 7% relative to eGFP injected controls; t = 5.6; 
p < 0.002; n = 12 mice) and in the medial frontal cortex (45 ± 3 
vs 96 ± 6%; t = 7.4, p < 0.0003; n = 8 mice; Figure 5B). Notably, 
because AAV2-miSyn4 is only effective close to the injection site 
and α-synuclein in Thy1-SNCA mice is widely overexpressed 
throughout the nervous system (32), we did not study behavior 
in these animals.
We turned to a second model of α-synuclein overexpression 
using viral hSNCA overexpression using AAV2. Viral overex-
pression of hSNCA in the substantia nigra can model behavioral 
aspects of PD (9). To test whether behavioral deficits induced by 
hSNCA overexpression in substantia nigra can be alleviated by 
AAV2-miSyn4, four groups of mice were unilaterally injected 
into the substantia nigra with (1) AAV2-eGFP (vector controlling 
for miSyn4), (2) AAV2-mCherry (vector controlling for hSNCA), 
(3) AAV2-hSNCA with AAV2-eGFP, or (4) AAV2-hSNCA with 
AAV2-miSyn4. Ninety days after virus injection, a series of 
FigUre 1 | rna interference of α-synuclein. (a) Design of RNAi molecules based on limited potential off-targeting revealed eight possible sequences, labeled 
miSyn1–8 (see Tables 1 and 2). miSyn1, 2, 3, 4, and 8 targeted to hSNCA140 and splice variants hSNCA126, 112, and 98. (B) In HEK293 cells, western blotting 
revealed marked knockdown of hSNCA for miSyn3–5; n = 6 samples per lane. Scrambled RNAi used a positive control. (c) miSyn4 knocked down hSNCA in vivo 
by qPCR; n = 8 samples. (D) miSyn4 did not affect mouse SNCA by qPCR; n = 9 samples. *p < 0.05 by t-test.
TaBle 1 | rna-interference sequences.
clone sequence
miSyn1 CTCGAGTGAGCGATGGGAGTGGCCATTCGATGAACTGTAAAGCCACAGATGGGTTCGTCGAATGGCCACTCCCAGCGCCTACTAG
miSyn2 CTCGAGTGAGCGAGGGAGTGGCCATTCGACGATACTGTAAAGCCACAGATGGGTGTCGTCGAATGGCCACTCCCACGCCTACTAG
miSyn3 CTCGAGTGAGCGTGGGTATCAAGACTACGAATTACTGTAAAGCCACAGATGGGTGGTTCGTAGTCTTGATACCCTCGCCTACTAG
miSyn4 CTCGAGTGAGCGTAGGGTATCAAGACTACGAATACTGTAAAGCCACAGATGGGTGTTCGTAGTCTTGATACCCTTCGCCTACTAG
miSyn5 TCTAGTAGGCGGACCAAAGAGCAAGCGACAAATCCCATCTGTGGCTTTACAGATTTGTCACTTGCTCTTTGGTTCGCTCACTCGAG
miSyn6 TCTAGTAGGCGATGCCTGTGGATCCCGACAATACCCATCTGTGGCTTTACAGTATTGTCAGGATCCACAGGCAGCGCTCACTCGAG
miSyn7 TCTAGTAGGCGAACCAAGGAGGGAGTGGCGCAACCCATCTGTGGCTTTACAGTTACACCACTCCCTCCTTGGTGCGCTCACTCGAG
miSyn8 TCTAGTAGGCGAAGGCCAAGGAGGGAGTCGTAACCCATCTGTGGCTTTACAGTCACAACTCCCTCCTTGGCCTGCGCTCACTCGAG
A specificity-focused siRNA design algorithm identified microRNAs with minimal off-targeting potential labeled miSyn1–8.
3
Kim et al. RNAi of hSNCA
Frontiers in Neurology | www.frontiersin.org January 2017 | Volume 8 | Article 13
FigUre 3 | example immunohistochemistry from a mouse injected in 
the substantia nigra (top panel; scale bar—100 µm) with aaV-misyn 
(green; bottom panel; scale bar—10 μm). Tyrosine hydroxylase in red.
FigUre 2 | Virally mediated knockdown of α-synuclein. (a) Plasmid 
map of α-synuclein for AAV2-miSyn4. (B) Example of hSNCA in HEK293 
cells transfected with AAV2.miSyn4 and hSNCA (right most lane); B-actin is 
present in all three lanes. (c) Example of semi-qPCR for miSyn4 from 
injected and uninjected cerebral hemispheres injected with AAV2-miSyn4.
TaBle 2 | misyn target sequence characteristics.
misnca candidates silencing? Target sequence conserved?
α-synuclein snca 126 snca 112 snca 98 Mouse/rat β-synuclein γ-synuclein a30P e46K a53T
Optimal Yes Yes Yes Yes No/no No No Yes Yes Yes
miSNCA1 No Yes Yes Yes No/no No No Yes Yes Yes
miSNCA2 No Yes Yes Yes No/no No No Yes Yes Yes
miSNCA3 Yes Yes Yes Yes No/no No No Yes Yes Yes
miSNCA4 Yes Yes Yes Yes No/no No No Yes Yes Yes
miSNCA5 Yes Yes Yes Yes Yes/yes No No Yes Yes Yes
miSNCA6 No Yes No No Yes/no No No Yes Yes Yes
miSNCA7 Marginal No Yes No Yes/yes No No Yes No No
miSNCA8 No Yes Yes Yes Yes/yes Yes Yes Yes Yes Yes
Summary of each clone’s target sequence, efficacy of silencing, coverage of major splice variants of human α-synuclein, and coverage of dominant pathogenic mutations.
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behavioral tests were performed and hSNCA levels were exam-
ined by western blot.
AAV2-hSNCA was expressed in the substantia nigra, 
and AAV2-miSyn4 reduced hSNCA expression (Figure  6A). 
Western blots indicated that overexpressed hSNCA was reduced 
in mice injected with AAV2-hSNCA and AAV2-miSyn4 com-
pared to mice injected with AAV2-hSNCA alone (Figure 6B; 
FigUre 5 | aaV2-misyn4 decreases α-synuclein in Thy1-SNCA mice 
after 90 days. (a) Injection of AAV2-miSyn4 into the substantia nigra 
decreased hSNCA immunoreactivity using a human-specific synuclein 
antibody, (B) qPCR of α-synuclein from Thy1-SNCA mice revealed significantly 
less α-synuclein in mice injected with AAV2-miSyn4 in both the substantia 
nigra and the cerebral cortex. Sample size as shown; *p < 0.05 by t-test.
FigUre 4 | aaV2-misyn4 is tolerable to mice after 90 days. (a) Mice injected with AAV2-miSyn4 had similar numbers of TH+ and GFAP+ cells by immuno-
histochemistry compared to uninjected sides or AAV-eGFP mice. Cell counts per high power field. (B) No behavioral differences were observed between mice 
injected with AAV-eGFP or AAV2-miSyn4 in open-field testing, number of rearings, rotarod latency, balance beam pole-traverse, balance beam slips, or contralateral 
circling. n = 5 mice per group; black bars—AAV-miSyn2; gray bars—AAV-eGFP, white bars—uninjected side.
5
Kim et al. RNAi of hSNCA
Frontiers in Neurology | www.frontiersin.org January 2017 | Volume 8 | Article 13
0.43  ±  0.096 vs 0.015  ±  0.0006; ~4% expression; t  =  4.68, 
p < 0.0001; n = 8).
We next used the cylinder test to evaluate forelimb use 
asymmetry in these mice 90  days after unilateral injection of 
AAV2-eGFP, AAV2-mCherry, AAV2-hSNCA with AAV2-eGFP, 
or AAV2-hSNCA with AAV2-miSyn4 (9). While mice with 
unilateral injection of AAV2-hSNCA showed a preference for 
ipsilateral forelimb use and a deficit in contralateral forelimb use, 
mice with unilateral injection of AAV2-hSNCA + AAV2-miSyn4 
showed no preference or deficit on forelimb use (Figure  6C; 
44.3 ± 6 vs 55.7 ± 6%, two-way ANOVA with Tukey post hoc test, 
p = 0.017; n = 10). AAV2-hSNCA did not reliably impair rotarod 
and open-field circling; hence, we did not focus on these assays. 
Taken together, these data indicate that virally expressed miSyn4 
can attenuate some effects of hSNCA overexpression in vivo in 
two animal models.
DiscUssiOn
In the present study, we designed an RNAi-based approach to 
decrease hSNCA in mouse models. We used bioinformatic algo-
rithms to engineer siRNA targeting hSNCA and used AAV2 to 
express this molecule in vivo. We found that it could be tolerated 
in mice and could effectively reduce expression of hSNCA in two 
mouse models that overexpress hSNCA. α-Synuclein appears 
to be involved in endocytosis of vesicles (33). Accelerated fibril 
formation appears to contribute to Lewy-body formation in PD 
(34, 35), and these fibrils could be transmissible through prion-
like mechanisms (36–38). α-Synuclein has been implicated as 
a key molecule in PD and thus is an attractive target for novel 
therapeutic interventions (4, 39). Although there have been 
several attempts to decrease α-synuclein through a variety of 
methods, ours is the first to demonstrate in  vivo effectiveness 
against human α-synuclein.
FigUre 6 | aaV2-misyn4 decreases human α-synuclein expression by 
aaV2-hsnca. (a) Injection of AAV2-hSNCA into substantia nigra induced 
hSNCA immunoreactivity, and co-injection of AAV2-hSNCA and AAV2-
miSyn4 decreased hSNCA immunoreactivity. (B) Western blot of hSNCA 
from mice with co-injection of AAV2-hSNCA and AAV2-miSyn4 revealed 
significantly less hSNCA in mice injected with AAV2-miSyn4 in the substantia 
nigra. (c) Silencing of hSNCA expression in the substantia nigra by 
AAV2-miSyn4 improved motor deficits in AAV2-hSNCA injected mice, as 
measured by forelimb preference. *p < 0.05 via general linear model with 
Tukey post hoc test.
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Prefacing this work is extensive data on mice with 
α-synuclein knocked out; in these mice, there is no neuro-
degeneration and mild decreases in dopamine content  (11). 
However, α-synuclein knockout mice can be resistant to 
neurotoxins such as MPTP and 6-OHDA (13, 40). These 
data indicate that α-synuclein could be an attractive target 
for neuroprotective therapies. RNAi approaches targeting 
α-synuclein have had mixed results. Knocking down α-synuclein 
in primates by direct infusion of siRNA also resulted in 
decreased α-synuclein expression without neurotoxicity (19). 
However, AAV-mediated shRNA against rat α-synuclein 
reported marked reduction in TH+ neurons in the midbrain 
(16). A subsequent study targeting rat α-synuclein found no 
toxicity and reported neuroprotection in a rotenone model of 
PD (20). RNAi approaches targeting human α-synuclein in rats 
have also resulted in some toxicity and inflammation that may 
have been dependent on the level of shRNA expression (17, 
18, 21). Here, we use bioinformatic approaches to minimize 
off-targeting and knockdown human α-synuclein in mice. Our 
results are novel on several fronts. First, whereas prior work 
was in rats or primates, our work is in mice, enabling us to 
provide new data in transgenic mice overexpressing α-synuclein 
(32). Second, whereas some prior work in rats had toxicity or 
inflammation (16, 18, 21), our approach, which harnessed an 
informatics approach, did not find evidence of toxicity or motor 
deficits. Third, we provide novel evidence that in two mouse 
models we can decrease α-synuclein overexpression as well as 
some aspects of behavior.
We decreased α-synuclein in a restricted cell-population 
around our injection site in the midbrain. We intentionally did 
not knockdown mouse synuclein (13, 14). This limits our ability 
to study if AAV2-miSyn4 protects against neurotoxins in mouse 
models (41). α-Synuclein is expressed in the cortex, as well as 
the midbrain (42), and may contribute to cognitive impairments 
in PD (43–45) and DLB (15, 46). Our data indicate that virally 
mediated RNAi for hSNCA was effective in the cortex as well 
as the midbrain. These data could be helpful in developing 
neuroprotective strategies for human synucleinopathies such as 
PD and DLB.
We used a virus with AAV2/5, which we have used in the past 
to robustly and reliably express genes in the rodent brain (26, 
43, 47, 48). While there are many serotypes of AAV that can be 
effective in the brain (49), AAV2 is currently in clinical trials 
for PD (NCT# NCT0162158). Future studies will compare AAV 
serotypes to achieve maximal expression with minimum toxicity.
Our study has several limitations. First, we use two models of 
α-synuclein overexpression in mice: the Thy1-SNCA mouse and 
viral hSNCA overexpression (32, 50). These models are very dif-
ferent from clinical PD, which can be quite complex and involve 
many cellular and circuit processes. The Thy1-SNCA mouse 
expresses α-synuclein under the Thy1 promoter at very high 
levels. These may include non-dopaminergic neurons, neurons 
outside the nigra, and may encompass non-neuronal tissues 
such as glia and endothelial cells. Unraveling these interactions 
will likely involve systematically manipulating α-synuclein in 
each of these cell types, but could have particularly relevance to 
PD as well as other synucleinopathies, such as multiple-systems 
atrophy and dementia with Lewy bodies (4, 15). Although few 
studies have explored viral SNCA overexpression in mice (9), 
we find behavioral recovery with forepaw preference in the 
viral hSNCA model, constraining our ability to find evidence of 
neuroprotection. Our behavioral effects are limited to this assay; 
mostly because hSNCA mice did not have reliable motor deficits 
in other tests of motor function in our hands. One challenge 
is that mouse models of α-synuclein overexpression in mice do 
not consistently involve robust motor impairments at a young 
age; indeed, often the animals must be aged or involve multiple 
mutations, or broad synuclein overexpression in many tissues 
and brain areas (15, 30, 32). Future work could examine motor 
deficits in these animals as they age, as well as examine mice with 
synuclein mutations or protofibril deposition (7, 37). We also 
did not look directly at cell death in our hSNCA overexpression 
experiments. Human SNCA overexpression can lead to marked 
cell death in rats, although in mice this appears to be somewhat 
less (9, 51). Furthermore, synuclein can affect complex aspects 
of dopamine neuron biology, including vesicles and dopamine 
release (52). Notably, we determine how levels of α-synuclein 
measured in hSNCA overexpressing animals are affected by 
cell death. Notably, these experiments are all done in mice and 
do not indicate whether this approach would be well received 
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should the virus be injected in to humans. Future work will be 
required to establish whether RNAi is a safe and effective strategy 
in humans in vivo.
MaTerials anD MeThODs
micrornas
microRNAs were designed using the siSPOTR tool (23) to 
maximize interference potency and minimize potential off-target 
sequences (24). Eight potential sequences (miSyn1–8) targeting 
exons of the human α-synuclein gene (SNCA; OMIM). These 
sequences had low off-targeting potential (Table  1). Artificial 
miRNA expression cassettes were cloned into Tb:mU6 expression 
plasmids, and recombinant AAV serotype 2/5 vectors (AAV2-
miSyn and AAV2-miSCA1) were generated by the University 
of Iowa Vector Core facility as previously described (53). AAV 
vectors were resuspended in buffer, and titers were determined 
by qPCR. Control vectors were identical plasmids without miSyn 
expression cassettes. Viruses were stored in a salt solution and 
dialyzed prior to injection (54).
In Vitro analysis
HEK293 cells were obtained from the Gene Vector Core at 
the University of Iowa. Cells were plated with equal density 
(400,000  cells/ml) in 24-well plates. The next day, cells were 
cotransfected with PCEP4-SNCA  +  miSyn candidates using 
lipofectamine 2000 transfection reagent. Forty-eight hours later, 
cells were lysed for analysis of protein expression by western blot 
and RNA expression by qPCR. Control cells expressed PCEP4-
SNCA  +  a U6 scrambled snRNA control (to balance RNA 
content) or were untreated HEK293 cells.
animals
Sixteen wild-type ~3-month-old C57/B6 male mice were used 
to assess the expression and tolerability of miSyn. Twenty-one 
additional transgenic ~3-month-old Thy1-SNCA mice were 
used to test miSyn in transgenic models of α-synuclein (32, 55). 
These mice express α-synuclein in a variety of tissues under 
the Thy1 promoter and have severe behavioral deficits due to 
ubiquitous α-synuclein overexpression (31). Forty 3-month-old 
wild-type mice were injected with AAV2-hSNCA, AAV2-
miSyn4, or control viruses (an identical vector to AAV-miSyn4 
without miRNAi, with GFP driven under the CMV promoter) 
to test if miSyn4 could rescue behavioral deficits caused by 
AAV2-hSNCA overexpression. All animals were housed with 
littermates using a 12-h light/dark cycle. This study was car-
ried out in strict accordance with the recommendations in 
the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. The protocol was approved by the 
Institutional Animal Care and Use Committee at the University 
of Iowa (protocol # 4071105). All surgery was performed under 
ketamine and xylazine anesthesia, and all efforts were made to 
minimize suffering.
aaV injections
Mice were anesthetized with ketamine (100  mg/kg) and 
xylazine (10  mg/kg) and placed in a stereotaxic frame. The 
scalp was retracted, bregma and lambda were leveled, and a 
small craniotomy was drilled. Coordinates for the substantia 
nigra were AP: −3.3  mm, ML: −1.2  mm, and DV: −4.5  mm 
and for cortical injections were AP: +1.5 mm, ML: −1.0 mm, 
and DV: −1.5 mm. To locally overexpress wild-type hSNCA in 
the mouse substantia nigra, an hSNCA (BC013293.2) vector 
driven by CAG promoters was designed with recombinant 
AAV2/6 vectors (serotype 2 genome/serotype 6 capsid; this 
vector was distinct from AAV2/5 made by the University of 
Iowa vector core for miSyn above) (9) CAG-hSNCA-WPRE 
and CAG-mCherry-WPRE vectors were produced and puri-
fied in Vector BioLabs (Philadelphia, PA, USA). AAV titers 
were  ~1013  GC/ml by qPCR.
histology
Mice were anesthetized with a ketamine/xylazine mix and 
transcardially perfused with 20  ml of 0.9% cold saline. For 
histological analyses, mice were decapitated, and brains were 
removed and postfixed overnight in 4% paraformaldehyde. 
Brains were stored in a 30% sucrose solution at 4°C, sectioned on 
a freezing microtome at 40 µm thickness and stored at −20°C in 
a cryoprotectant solution. For RNA sample preparation, the brain 
was triturated in 1 ml of TRIzol (Life Technologies, Grand Island, 
NY, USA), flash frozen in liquid nitrogen, and stored at −80°C 
until used. RNA was isolated from tissue expressing eGFP under 
fluorescence microscopy using 1 ml of TRIzol. RNA quantity and 
quality was measured using a NanoDrop® ND-1000 (Nanodrop, 
Wilmington, DE, USA).
immunohistochemical analyses
Free-floating coronal sections (40-µm thick) were washed in phos-
phate-buffered saline at room temperature and blocked for 1 h in 
10% serum and 0.03% Triton X-100 in phosphate-buffered saline. 
Sections were incubated with primary antibody in 2% serum and 
0.03% Triton-X in phosphate-buffered saline overnight at 4°C. 
Primary antibodies to tyrosine hydroxylase (AB152; Millipore; 
1:500), NeuN (MAB377; Millipore; 1:200), GFAP (1:400; 
13-0300; Invitrogen), and hSNCA (MAB5320; Millipore; 1:400) 
were incubated at 2% serum and 0.03% Triton-100 in phosphate-
buffered saline for 1 h at room temperature. Sections were stained 
with Alexa Fluor fluorescent secondary antibodies matched to 
the host primary (Alexa Fluor 488, 555, 568, 633) (1:400; Jackson 
Immunoresearch, West Grove, PA, USA) in 2% serum and 0.03% 
Triton-X at room temperature for 1 h. All sections were mounted 
onto Superfrost Plus slides (Fischer Scientific, Pittsburgh, PA, 
USA) and cover slipped with Fluoroshield with DAPI (F6057; 
Sigma). Images were captured on Leica Leitz Digital Module R 
fluorescent microscope (Leica Microsystems, Buffalo Grove, IL, 
USA) connected to a Olympus DP72 camera (Olympus, Melville, 
NY, USA) using the Olympus DP2-BSW software (Olympus). 
Immunopositive cells were counted per field of view at 40× using 
ImageJ by two blinded investigators. Cell counts were compared 
via t-tests.
semiquantitative Pcr
Reverse transcription (High Capacity cDNA Reverse 
Transcription Kit; Applied Biosystems, Foster City, CA, USA) 
8Kim et al. RNAi of hSNCA
Frontiers in Neurology | www.frontiersin.org January 2017 | Volume 8 | Article 13
was performed on total RNA collected from brain regions of 
interest using a standard stem-loop PCR primer (56) designed 
to identify miSyn4 or hSNCA. Complementary DNA was 
subjected to reverse transcriptase-PCR with a standard reverse 
primer (5′ GTGCAGGGTCCGAGGT) and a forward primer 
(5′ CACAGATGGGTG ATTGCTTGCTGC) to identify miSyn4 
expression compared with β-actin. Random-primer first-strand 
complementary DNA synthesis was performed using 1  µg of 
total RNA (High Capacity cDNA Reverse Transcription Kit; 
Life Technologies) per the manufacturer’s instructions. Assays 
were performed on a sequence detection system using primers/
probe sets specific for mouse SNCA (Mm01188700_m1), hSNCA 
(Hs002040907_m1), or mouse β-actin (Mm01205674_g1) (ABI 
Prism 7900 HT and TaqMan 2× Universal Master Mix; Life 
Technologies).
Western Blot analysis
Protein was harvested using radioimmunoprecipitation assay 
buffer (Pierce, ThermoScientific, Pierce, Rockford, IL, USA) and 
1× protease inhibitor using standard techniques and quantified 
using DC Protein Assay (BioRad Laboratories, Hercules, CA, 
USA). Protein extracts were separated on a 4–12% Bis-Tris 
Gel with 2-(N-morpholino)ethanesulfonic acid (Invitrogen, 
Carlsbad, CA, USA) and transferred to Immobilon 0.45-µm 
polyvinylidenefluoride transfer membranes (Millipore, Bedford, 
MA, USA). Primary antibodies to hSNCA (1:1,000; S3062; Sigma 
or 1:2,000; MAB5320; Millipore) and β-actin (1:10,000; A5441; 
Sigma, St. Louis, MO, USA) were used. Blots were developed using 
electrochemiluminescence Prime Western Blotting Detection 
System (GE Healthcare, Buckinghamshire, UK) and quantified 
by VersaDoc 5000 MP (BioRad Laboratories). All samples were 
compared via t-tests.
Behavioral analysis
All behavioral analyses were done at 90  days post-viral 
injection (AAV2-miSyn4, AAV2-mCherry, or AAV2-eGFP). 
Behavioral analyses for mice included testing of open-field 
activity, balance beam testing, and rotarod. Rodents were 
placed in an open-field arena, and their first 20 min of behavior 
was captured via real time video tracking to prevent habitua-
tion and observe activity in novel environment. Balance beam 
testing was performed as mice traversed a 30″ narrow beam. 
The time to traverse the beam and the number of falls were 
scored as failures. Rodents were tested on a rotarod apparatus 
(Med Associates, St. Albans, VT, USA) with three trials per 
day as acceleration was uniformly increased from 4 to 40 rpm 
over 5  min. The trials were stopped at 500  s. Latency to fall 
(or if mice hung on for two consecutive rotations without 
running) was recorded for each mouse per trial. Amphetamine 
based circling was measured 30  min after injected 1  mg/kg 
of amphetamine IP and by counting the number of circles in 
10 min. All behavioral comparisons were performed via t-tests 
or a generalized linear mode.
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